Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma

Area of Science:

• Genomics
• Oncology
• Molecular Biology

Background:

• Therapy development for adult diffuse gliomas is limited by incomplete knowledge of driving genetic alterations and suboptimal classification.
• Accurate disease classification and understanding of molecular drivers are crucial for advancing glioma treatment.

Purpose of the Study:

• To define the complete set of genes associated with diffuse gliomas (grades II-IV).
• To utilize molecular profiles for improved disease classification, identification of molecular correlations, and insights into low- to high-grade progression.
• To identify clinically relevant molecular subsets within diffuse gliomas.

Main Methods:

• Analysis of whole-genome sequencing data from 1,122 diffuse gliomas from The Cancer Genome Atlas (TCGA).
• Utilized DNA methylation profiles to recapitulate and refine glioma classification based on IDH mutation and 1p/19q co-deletion status.
• Investigated associations between genetic alterations (e.g., ATRX, TERT promoter mutations) and molecular features (e.g., telomere length, DNA demethylation).

Main Results:

• ATRX mutations, but not TERT promoter mutations, were associated with increased telomere length.
• DNA methylation profiling confirmed established glioma subtypes (IDH-mutant, 1p/19q co-deleted) and identified novel molecular subsets.
• A distinct subtype of IDH-mutant glioma exhibited DNA demethylation and was linked to poor outcomes.
• A subset of IDH-wild-type diffuse gliomas displayed molecular similarities to pilocytic astrocytoma, associated with more favorable survival.

Conclusions:

• Comprehensive genomic and molecular profiling refines diffuse glioma classification, identifying clinically relevant subtypes.
• Understanding these cohesive molecular disease groups, including IDH-mutant and IDH-wild-type subsets, offers insights into glioma progression and potential therapeutic targets.
• Improved classification and understanding of molecular drivers can aid in developing more effective therapies and improving patient outcomes for diffuse gliomas.